Oral Solid Drug Continuous Manufacturing

by , | May 6, 2020 | Life Sciences & Medical | 0 comments

With the global focus around the COVID-19 Coronavirus pandemic, manufacturers in the pharmaceutical and biotech industries have been racing to find both treatments and preventive vaccines.

Batch processing has been the historical method of production for these Life Science companies. Continuous processing, which holds the promise of greater development and production flexibility, has continued to become a reality.

In a May 19 BioPharma Asia webinar, Continuous Manufacturing as a Default Platform for Oral Solid Drug Products, Emerson’s Bob Lenich will team up with Johnson and Johnson Senior Principal Engineer Lawrence De Belder to discuss the path to continuous manufacturing for these types of medicines. Register here to join Lawrence and Bob or to watch the webinar later, on demand.

They will discuss:

…different strategies to handle a [drug development] pipeline that can be highly dynamic. Different techniques will be discussed that can be used to bring products with bad flow properties into a continuous process. Impact of different equipment in development, clinical and commercial environment will be detailed out, and mitigations will be proposed to overcome these differences. All will be placed in front of a background of regulatory requirements, changing market demand, and evolving strategies of equipment vendors.

Lawrence will discuss differences in approach to continuous manufacturing versus batch manufacturing and considerations through the product development lifecycle—including development, technology transfer on up to commercial manufacturing. These changes enable great flexibility, modularity and more.

Bob will further explore this operational flexibility to adjust production capacity in response to rapidly changing demand forecast, unexpected failures in late stage clinical trials or faster than expected clinical adoption.

The change from batch to continuous designed around an intensified and simplified bioprocess requires smaller equipment that can be scaled based on time and parallelization rather than volumetric expansion. He’ll describe some of the innovations to enable this shift including single-use technologies and portable processing equipment for greater operational flexibility and decentralized production.

They will have much more to share so register today to learn more about considerations in continuous manufacturing. Visit the Control Systems and Software for the Life Sciences Industry section on Emerson.com for more on the technologies and solutions to help drive the shift from batch to continuous processing.

Popular Posts



Featured Expert

Related Posts

Follow Us

We invite you to follow us on Facebook, LinkedIn, Twitter and YouTube to stay up to date on the latest news, events and innovations that will help you face and solve your toughest challenges.

Do you want to reuse or translate content?

Just post a link to the entry and send us a quick note so we can share your work. Thank you very much.

Our Global Community

Emerson Exchange 365

The opinions expressed here are the personal opinions of the authors. Content published here is not read or approved by Emerson before it is posted and does not necessarily represent the views and opinions of Emerson.

PHP Code Snippets Powered By : XYZScripts.com